Short answer
Eton Pharmaceuticals, Inc. (ETON) filed an 8-K current report with the SEC on May 19, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement). U.S. commercialization rights begin September 26, 2026, expanding Eton’s orphan-drug portfolio with IMPAVIDO.
Eton Pharmaceuticals, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- U.S. commercialization rights begin September 26, 2026, expanding Eton’s orphan-drug portfolio with IMPAVIDO
- Fixed fees total $4.25 million through March 31, 2032, creating staged cash obligations
- Additional milestone payments up to $4.0 million tied to cumulative net sales reaching $50.0 million to $200.0 million
- Eton retains 45% of net sales up to $7.0 million annually and 50% above $7.0 million before marketing expenses
- 2025 U.S. sales were $8.1 million, providing an existing commercial base while Supplier covers product and regulatory costs
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Eton Pharmaceuticals, Inc. 8-K filings
Get the next ETON 8-K as it lands
Follow ETON for push alerts, or ask the research agent what this filing means.